Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-3
pubmed:dateCreated
2008-7-28
pubmed:abstractText
C6 glioma cells were treated with clinically relevant concentrations of valproic acid (0.5 or 1.0 mM) for 1-7 days and RT-PCR used to examine expression of the melatonin MT(1) receptor and selected epigenetic modulators. Valproic acid caused significant time-dependent changes in the mRNA expression of the melatonin MT(1) receptor, histone deacetylase (HDAC) 1, 2 and 3, and methyl CpG binding protein 2 (MeCP2). A structurally distinct HDAC inhibitor, trichostatin A, also caused a significant concentration-dependent induction of melatonin MT(1) receptor mRNA expression, suggesting involvement of an epigenetic mechanism. The ability of clinical concentrations of valproic acid to significantly alter melatonin MT(1) receptor expression, suggests a role for this receptor in the diverse neuropharmacological and oncostatic effects of this agent.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Hdac1 protein, rat, http://linkedlifedata.com/resource/pubmed/chemical/Hdac2 protein, rat, http://linkedlifedata.com/resource/pubmed/chemical/Histone Deacetylase 1, http://linkedlifedata.com/resource/pubmed/chemical/Histone Deacetylase 2, http://linkedlifedata.com/resource/pubmed/chemical/Histone Deacetylase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Histone Deacetylases, http://linkedlifedata.com/resource/pubmed/chemical/Hydroxamic Acids, http://linkedlifedata.com/resource/pubmed/chemical/Mecp2 protein, rat, http://linkedlifedata.com/resource/pubmed/chemical/Methyl-CpG-Binding Protein 2, http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger, http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Melatonin, MT1, http://linkedlifedata.com/resource/pubmed/chemical/Repressor Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Valproic Acid, http://linkedlifedata.com/resource/pubmed/chemical/histone deacetylase 3, http://linkedlifedata.com/resource/pubmed/chemical/trichostatin A
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0014-2999
pubmed:author
pubmed:issnType
Print
pubmed:day
28
pubmed:volume
589
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
45-8
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:18550052-Animals, pubmed-meshheading:18550052-Brain Neoplasms, pubmed-meshheading:18550052-Cell Line, Tumor, pubmed-meshheading:18550052-Dose-Response Relationship, Drug, pubmed-meshheading:18550052-Enzyme Inhibitors, pubmed-meshheading:18550052-Epigenesis, Genetic, pubmed-meshheading:18550052-Gene Expression Regulation, Enzymologic, pubmed-meshheading:18550052-Gene Expression Regulation, Neoplastic, pubmed-meshheading:18550052-Glioma, pubmed-meshheading:18550052-Histone Deacetylase 1, pubmed-meshheading:18550052-Histone Deacetylase 2, pubmed-meshheading:18550052-Histone Deacetylase Inhibitors, pubmed-meshheading:18550052-Histone Deacetylases, pubmed-meshheading:18550052-Hydroxamic Acids, pubmed-meshheading:18550052-Methyl-CpG-Binding Protein 2, pubmed-meshheading:18550052-RNA, Messenger, pubmed-meshheading:18550052-Rats, pubmed-meshheading:18550052-Receptor, Melatonin, MT1, pubmed-meshheading:18550052-Repressor Proteins, pubmed-meshheading:18550052-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:18550052-Time Factors, pubmed-meshheading:18550052-Valproic Acid
pubmed:year
2008
pubmed:articleTitle
Clinically relevant concentrations of valproic acid modulate melatonin MT(1) receptor, HDAC and MeCP2 mRNA expression in C6 glioma cells.
pubmed:affiliation
Department of Psychiatry and Behavioural Neurosciences, McMaster University, HSC-4N77, Hamilton, ON, Canada.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't